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 Is hepcidin the star player 
in iron metabolism 
in chronic kidney disease? 
 Yasuhiro  Hamada 1 , 2 and  Masafumi  Fukagawa 1 
 It is well known that abnormal iron metabolism contributes to the 
development of anemia in chronic kidney disease (CKD) patients. 
Hepcidin is a circulating peptide produced in the liver that regulates 
efflux of iron from the cells. Ashby  et al. measured the serum level of 
hepcidin using a new assay. Although the new assay produced mixed 
results and needs to be verified, these data suggest that hepcidin is not 
the only star player in iron metabolism in CKD. 
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 Maintenance of adequate iron balance is 
crucial for health. Hepcidin is one of the 
primary regulators of systemic iron home-
ostasis and is expressed predominantly in 
the liver, with lower expression detected in 
other organs, such as kidney, heart, and 
brain.  e major action of hepcidin is to 
internalize and degrade the iron efflux 
transporter ferroportin, expressed on all 
iron-exporting cells. 1 Accordingly, a high 
hepcidin level leads to the suppression of 
intestinal iron absorption and iron release 
from  macrophages and hepatocytes, 
whereas a low concentration of hepcidin 
leads to acceleration of iron release from 
these cells. Several factors, such as iron 
stores, in% ammation, anemia, and hypoxia, 
have been identi& ed as potential regulators 
of hepcidin. In addition, it has recently 
been demonstrated that bone morphoge-
netic protein (BMP) pathways play signi& -
cant roles in the regulation of hepcidin. 
 The human hepcidin gene ( HANP ) 
encodes a precursor protein of 84 amino 
acids, preprohepcidin. 2 Preprohepcidin 
undergoes enzymatic cleavage, resulting 
in a protein of 64 amino acids, prohepci-
din.  e biologically active 25-amino acid 
form, hepcidin-25, is then produced by 
post-translational processing.  Additional 
degradation results in the production of 
two isoforms, hepcidin-20 and hepcidin-
22. 3 However, the biological roles of these 
two molecules are not yet known. 
 Measurement of serum hepcidin levels 
was a major issue until recently. In animal 
studies, hepcidin mRNA expression in the 
liver has been the preferred method. 4 Many 
human studies have already been published 
using a commercially available enzyme-
linked immunosorbent assay kit that uses 
antibodies directed against prohepcidin. 5 
However, the diagnostic use and interpreta-
tion of the data obtained by these measure-
ments have been controversial because 
serum prohepcidin levels may not correlate 
well with those of hepcidin-25, the active 
form. Measurement of hepcidin-25 needed 
to overcome several technical di6  culties, 
such as small size and limited availability of 
the antigen. Recently, hepcidin-25 assays 
based on mass spectroscopic techniques, 
surface-enhanced laser desorption /
 ionization time-of-% ight mass spectrometry 
(SELDI-TOF MS) and liquid chromatogra-
phy tandem mass  spectrometry (LC-MS /
 MS), have been reported. 6,7 However, these 
assays have not been widely available, 
because highly specialized and expensive 
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 equipment is needed. More recently, a 
 competitive immunoassay using anti-
 hepcidin-25 antibody has been reported. 8 
Ashby and associates 9 (this issue) now 
report a new competitive immunoassay 
using a  polyclonal rabbit anti-hepcidin-25 
antibody.  e assay is linear up to 200  ng / ml, 
with a detection limit of 0.6  ng / ml, and has 
no crossreactivity with prohepcidin.  ese 
speci& c assays for hepcidin-25 could be use-
ful for the elucidation of  physiological and 
pathophysiological roles and  regulations of 
hepcidin in iron  meta bolism. 
 Anemia, one of the most important 
complications of chronic kidney disease 
(CKD), is mainly due to relative erythro-
poietin de& ciency; however, these patients 
oB en have in% ammatory  conditions and 
disorders of iron metabolism.  us, it may 
be possible that these  abnormal states 
cause alterations of serum  hepcidin levels. 
There have been several reports that 
describe the relationships between hepci-
din levels and various abnormalities asso-
ciated with CKD. 4 – 6,9,10 With the use of 
diE erent assays, hepcidin levels in patients 
with CKD were found to be increased with 
reductions in glomerular & ltration rate but 
also seemed to depend on iron status, 
in% ammation, anemia, and erythropoietin 
therapy, as shown in  Figure 1 . In addition, 
one of the most attractive hypotheses is 
that serum hepcidin level may be a good 
predictor of erythropoietin resistance. 
 In the report by Ashby  et al. , 9 hepcidin-
25 level was inversely correlated with esti-
mated glomerular & ltration rate in CKD 
patients and was reduced by erythropoietin 
therapy, consistent with previous reports. 
Nevertheless, contrary to the hypothesis 
that hepcidin may be a useful predictor of 
erythropoietin resistance, there was no 
correlation between hepcidin-25 levels and 
erythropoietin dose.  e authors also dem-
onstrated con% icting data with their new 
speci& c assay for  hepcidin-25: (1) Healthy 
subjects had a diurnal pattern of hepcidin, 
but patients with CKD, regardless of dialy-
sis, showed no clear diurnal pattern. (2) 
 e relationship between hepcidin and fer-
ritin was con& rmed in predialysis patients, 
but the relationship was no longer observed 
in hemodialysis patients. (3) Although 
in% ammation has been well recognized to 
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increase hepcidin production, there was no 
correlation between hepcidin and in% am-
mation markers such as C-reactive protein 
and interleukin-6 in predialysis patients, 
nor in hemodialysis patients. (4) Plasma 
levels of growth diE erentiation factor 15 
(GDF15), a member of the BMP /
 transforming growth factor-  superfamily, 
were positively correlated with plasma 
hepcidin levels in predialysis but not in 
dialysis patients. 
  ese results suggest that iron regulation 
in CKD patients might be more complex 
than we initially thought. In CKD patients, 
there are several abnormal factors, some of 
which may increase, whereas others 
decrease, hepcidin levels. In dialysis 
patients, additional factors may further 
modify iron metabolism through or inde-
pendently of hepcidin. We still have no idea 
how these factors aE ect hepcidin and iron 
metabolism in these patients.  erefore, 
contrary to our initial expectations, hepci-
din may not be the major player in abnor-
mal iron  metabolism in CKD. Nevertheless, 
further studies with easier assays for hepci-
din-25 would certainly provide answers to 
these questions in the future, once sensitiv-
ity and specificity of these assays are 
 con& rmed. 
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 Fetuin – mineral complex: 
a new potential biomarker 
for vascular calcification? 
 Hirotaka  Komaba 1 and  Masafumi  Fukagawa 1 
 Vascular calcification is prevalent in dialysis patients and is associated with a 
high burden of cardiovascular disease. Fetuin-A is a potent inhibitor of 
vascular calcification, but the precise mechanism by which it mediates 
vascular calcification in uremia is unclear. Matsui and colleagues 
demonstrate that circulating fetuin-A forms fetuin – mineral complex in the 
serum of uremic rats and thereby inhibits vascular calcification. This 
suggests that fetuin – mineral complex may reflect extraosseous calcification 
stress, opening new perspectives on vascular calcification in uremia. 
 Kidney International (2009)  75, 874 – 876.  doi: 10.1038/ki.2009.52 
(CKD) receiving dialysis treatment and 
contributes to cardiovascular morbidity 
and mortality. Until recently, it has been 
believed that extraosseous calci& cation in 
uremic patients is a passive process of 
 calcium phosphorus precipitation caused 
by supersaturation; however, recent basic 
and clinical data support the notion that 
vascular calcification, like skeletal 
see original article on page 915
 Vascular calci& cation frequently occurs in 
patients with chronic kidney disease 
